Adenosine Phosphate

Adenosine Phosphate

SCHEMBL23093554

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Zn+2]

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 9/20 0.81
P2RY11 Q96G91 3/20 0.81
P2RY2 P41231 3/20 0.81
SRC P12931 2/20 0.81
SMN1; SMN2 Q16637 2/20 0.81
TRPM2 O94759 2/20 0.81
TAS1R3 Q7RTX0 2/20 0.81
TAS1R1 Q7RTX1 2/20 0.81
DNPH1 O43598 1/20 0.81
PRKAB2 O43741 1/20 0.81
LDHA P00338 1/20 0.81
ADRB2 P07550 1/20 0.81
FBP1 P09467 1/20 0.81
ADORA1 P30542 1/20 0.81
PRKAG1 P54619 1/20 0.81
PRKAA2 P54646 1/20 0.81
PDE4D Q08499 1/20 0.81
KCNH2 Q12809 1/20 0.81
PRKAA1 Q13131 1/20 0.81
PDE3A Q14432 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine Phosphate SCHEMBL29364783 0.99 P2RY1 (0.83) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL1356934 0.99 P2RY1 (0.83) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL145417 0.99 P2RY1 (0.83) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL353218 0.99 P2RY1 (0.83) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL7064977 0.98 P2RY1 (0.81) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL9068130 0.98 P2RY1 (0.81) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL5600449 0.98 P2RY1 (0.81) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL1164224 0.98 P2RY1 (0.81) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL1164292 0.98 P2RY1 (0.81) P2RY1P2RY11P2RY2SRCSMN1; SMN2
Adenosine Phosphate SCHEMBL5434021 0.98 P2RY1 (0.81) P2RY1P2RY11P2RY2SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTRE (US) 2022-10-20 US disclosed
CN-107920973-B Surface modification composition 株式会社LG生活健康 2021-05-07 CN disclosed
WO-2021050449-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTER (US) 2021-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS HTR6, FOS, API5 P2RY1 907/4885P2RY11 714/4885P2RY2 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.